Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Spencer

Showing results (11-20 of 111) with videos related to

Pageof 12
Sort By:
Frontiers in Aging Neuroscience|May 15, 2026
Systemic delivery of anti-sense oligonucleotide targeting α-synuclein for treatment in a mouse model of multiple system atrophyBrian Spencer, Bao Quach, Sahar Salehi, et al.
Plos One|September 29, 2021
Transcriptome analyses reveal tau isoform-driven changes in transposable element and gene expressionJennifer Grundman, Brian Spencer, Floyd Sarsoza, et al.
Research Square|November 24, 2025
Systemic delivery of anti-sense oligonucleotide targeting a-synuclein for the treatment of multiple system atrophyBrian Spencer, Bao Quach, Sahar Salehi, et al.
Neurobiology of Disease|May 10, 2025
Differential roles of human tau isoforms in the modulation of inflammation and development of neuropathologyBrian Spencer, Aaron Schueler, Daniel Sung, et al.
Expert Opinion on Biological Therapy|November 24, 2007
Novel strategies for Alzheimer's disease treatmentBrian Spencer, Edward Rockenstein, Leslie Crews, et al.
Methods in Molecular Biology (Clifton, N.J.)|April 25, 2012
Cell-to-cell transmission of α-synuclein aggregatesSeung-Jae Lee, Paula Desplats, He-Jin Lee, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
Anti-Sense Oligonucleotide as a Therapeutic for Synucleinopathies: Pharmacokinetic, Safety and Efficacy EvaluationRijwan U Ahammad, Brian Spencer, Bao Quach, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 22, 2026
Peptide-mediated delivery of an α-synuclein-targeting antisense oligonucleotide: Pharmacokinetics, safety, and central nervous system efficacy in a synucleinopathy modelRijwan U Ahammad, Bao Quach, Sahar Salehi, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 25, 2025
A splice-switching antisense oligonucleotide targeting APP reduces accumulation of α-synuclein in a mouse model of Parkinson's diseaseRijwan U Ahammad, Brian Spencer, Bao Quach, et al.
Molecular Neurodegeneration|September 24, 2015
A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophyBrian Spencer, Elvira Valera, Edward Rockenstein, et al.
Pageof 12

Showing results (11-20 of 111) with videos related to

Sort By:
Pageof 12
Frontiers in Aging Neuroscience|May 15, 2026
Systemic delivery of anti-sense oligonucleotide targeting α-synuclein for treatment in a mouse model of multiple system atrophyBrian Spencer, Bao Quach, Sahar Salehi, et al.
Plos One|September 29, 2021
Transcriptome analyses reveal tau isoform-driven changes in transposable element and gene expressionJennifer Grundman, Brian Spencer, Floyd Sarsoza, et al.
Research Square|November 24, 2025
Systemic delivery of anti-sense oligonucleotide targeting a-synuclein for the treatment of multiple system atrophyBrian Spencer, Bao Quach, Sahar Salehi, et al.
Neurobiology of Disease|May 10, 2025
Differential roles of human tau isoforms in the modulation of inflammation and development of neuropathologyBrian Spencer, Aaron Schueler, Daniel Sung, et al.
Expert Opinion on Biological Therapy|November 24, 2007
Novel strategies for Alzheimer's disease treatmentBrian Spencer, Edward Rockenstein, Leslie Crews, et al.
Methods in Molecular Biology (Clifton, N.J.)|April 25, 2012
Cell-to-cell transmission of α-synuclein aggregatesSeung-Jae Lee, Paula Desplats, He-Jin Lee, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
Anti-Sense Oligonucleotide as a Therapeutic for Synucleinopathies: Pharmacokinetic, Safety and Efficacy EvaluationRijwan U Ahammad, Brian Spencer, Bao Quach, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 22, 2026
Peptide-mediated delivery of an α-synuclein-targeting antisense oligonucleotide: Pharmacokinetics, safety, and central nervous system efficacy in a synucleinopathy modelRijwan U Ahammad, Bao Quach, Sahar Salehi, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 25, 2025
A splice-switching antisense oligonucleotide targeting APP reduces accumulation of α-synuclein in a mouse model of Parkinson's diseaseRijwan U Ahammad, Brian Spencer, Bao Quach, et al.
Molecular Neurodegeneration|September 24, 2015
A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophyBrian Spencer, Elvira Valera, Edward Rockenstein, et al.
Pageof 12